Business
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
OXNARD, Calif.--(BUSINESS WIRE)-- CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product
About this update from Currenc Group Inc.
[{"type":"text","content":" OXNARD, Calif.--(BUSINESS WIRE)--\nCURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan Berlent will participate in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17.\n\n\"The potential therapeutic benefits of psychedelics to treat mental health disorders is significant. I am very proud that we have been able to commence development of our psychedelics-based pharmaceutical clinical pipeline,\" Berlent said. “I look forward to sharing insights on how we will take advantage of our U.S. based, DEA-licensed Schedule 1 controlled substances facility, to deliver a number of psychedelic compounds in new ways that we believe will impact disease progression and improve the patient experience.”\n\nThe presentation can be viewed beginning at 7:00 a.m. EST on June 17 after registering at https://hcwevents.com/psychedelics/. It will also be available online for 90 days after the live presentation. To schedule a one-on-one meeting with management, please follow the instructions in the link above or reach out to your H.C. Wainwright representatives directly.\n\nAbout CURE Pharmaceutical Holding Corp.\n\nCURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.\n\nAs a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.\n\nForward Looking Statement\n\nStatements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually...